Literature DB >> 21185065

Percutaneous cryoablation of renal masses: impact of patient selection and treatment parameters on outcomes.

Gino J Vricella1, John R Haaga, Brittany L Adler, Edward E Cherullo, Susan Flick, Lee E Ponsky.   

Abstract

OBJECTIVES: To evaluate whether the trend in patient selection or perioperative parameters were associated with treatment outcomes after percutaneous cryoablation (PCA) of renal masses.
METHODS: We retrospectively analyzed our urological oncology database and identified 52 patients treated for a total of 54 renal masses. Univariate analysis was performed to evaluate whether the variables of age, gender, tumor size, number of probes used, total freezing time, preoperative creatinine, American Society of Anesthesia class, body mass index, or age-adjusted Charlson comorbidity index (CCI) score had an impact on the outcomes of treatment failure or the complication rate.
RESULTS: During a mean follow-up of 21 months, recurrence-free, overall, and disease-specific (based on radiographic follow-up and biopsy) survival were 96.2%, 98.1% and 100%, respectively. The mean age-adjusted CCI score for patients with postoperative complications was 6.5, compared with a mean score of 3.0 in patients without postoperative complications (P = .02). The complication rate was also significantly higher when a greater number of cryoprobes were used during PCA (P < .005). None of the variables analyzed were predictive of treatment failure.
CONCLUSIONS: Of the pre- and intraoperative variables studied, age-adjusted CCI score and number of cryoprobes used were the only variables with predictive value for outcomes in regard to treatment failure or complications. As investigators continue using cryoablation to treat renal masses, it is important to be able to completely and honestly counsel patients regarding the likelihood of complications and need for subsequent therapy in the setting of treatment failure.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21185065     DOI: 10.1016/j.urology.2010.08.016

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

1.  Thermoablation of Renal Masses: The Urologist's Perspective.

Authors:  Phillip H Abbosh; Sam B Bhayani
Journal:  Semin Intervent Radiol       Date:  2011-12       Impact factor: 1.513

Review 2.  Update on cryoablation for treatment of small renal mass: oncologic control, renal function preservation, and rate of complications.

Authors:  Anil Kapoor; Yuding Wang; Brad Dishan; Stephen E Pautler
Journal:  Curr Urol Rep       Date:  2014-04       Impact factor: 3.092

3.  Preoperative patient counseling for diagnostic renal biopsy and complications with renal radiofrequency ablation.

Authors:  Scott M Castle; Michael A Gorin; Vladislav Gorbatiy; Raymond J Leveillee
Journal:  World J Urol       Date:  2012-01-15       Impact factor: 4.226

4.  Skin-to-tumor Distance Predicts Treatment Failure of T1A Renal Cell Carcinoma Following Percutaneous Cryoablation.

Authors:  Simone L Vernez; Zhamshid Okhunov; Kamaljot Kaler; Ramy F Youssef; Rahul Dutta; Arkadiy Palvanov; Paras Shah; Kathryn Osann; David N Siegel; Igor Lobko; Louis Kavoussi; Ralph V Clayman; Jaime Landman
Journal:  Urology       Date:  2017-06-23       Impact factor: 2.649

5.  Efficacy of percutaneous cryoablation of renal cell carcinoma in older patients with medical comorbidities: Outcome study in 70 patients.

Authors:  Erich K Lang; Kan Karl Zhang; Quan Nguyen; Leann Myers; Mahamed Allaf; Ivan Colon
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

Review 6.  Role of tumor location in selecting patients for percutaneous versus surgical cryoablation of renal masses.

Authors:  Christopher J Long; Daniel J Canter; Marc C Smaldone; Tianyu Li; Jay Simhan; Boris Rozenfeld; Ervin Teper; David Y T Chen; Richard E Greenberg; Rosalia Viterbo; Robert G Uzzo; Alexander Kutikov
Journal:  Can J Urol       Date:  2012-10       Impact factor: 1.344

7.  Image-guided percutaneous renal cryoablation for stage 1 renal cell carcinoma with high surgical risk.

Authors:  Xiang Yan; Mingxin Zhang; Xiaoxiang Chen; Wang Wei; Rong Yang; Yang Yang; Weidong Gan; Hongqian Guo; Yang Wang; Guo-Ping Shi
Journal:  World J Surg Oncol       Date:  2015-06-10       Impact factor: 2.754

8.  Treatment of renal angiomyolipoma: pooled analysis of individual patient data.

Authors:  Teele Kuusk; Fausto Biancari; Brian Lane; Conrad Tobert; Steven Campbell; Uri Rimon; Vito D'Andrea; Aare Mehik; Markku H Vaarala
Journal:  BMC Urol       Date:  2015-12-28       Impact factor: 2.264

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.